Gefitinib
- PDF / 169,499 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 157 Views
1
S
Aspartate aminotransferase and alanine aminotransferase elevation: case report In a study of 14 patients conducted between February 2015 to November 2018, a patient [age and sex not stated] was described who developed aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevation while receiving gefitinib for resectable non-small cell lung cancer. The patient started receiving oral gefitinib 250 mg/day prior to the surgery. Later, the patient’s lab tests showed ≥ grade 3 AST/ALT elevation. Hence, gefitinib was discontinued [outcome and duration of treatment to reaction onset not stated]. Author comment: "Gefitinib (median exposure 1.4 mths) was well tolerated, 1 (8%) pt had ≥G3 AE, with G3 AST/ALT elevation." Tan A, et al. P1.17-07 Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study. Journal of Thoracic Oncology 14 (Suppl.): S609-S610, No. 10, Oct 2019. Available from: URL: http://doi.org/10.1016/j.jtho.2019.08.1281 [abstract] 803432762 Singapore
0114-9954/19/1778-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 9 Nov 2019 No. 1778
Data Loading...
